

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K/A**

(Amendment No. 1)

**CURRENT REPORT**

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2022

**VACCITECH PLC**

(Exact name of registrant as specified in its charter)

England and Wales  
(State or other jurisdiction  
of incorporation)

001-40367  
(Commission  
File Number)

Not Applicable  
(I.R.S. Employer  
Identification No.)

Vaccitech plc  
The Schrödinger Building  
Heatley Road  
The Oxford Science Park  
Oxford OX4 4GE  
United Kingdom

(Address of principal executive offices, including zip code)

+44 (0) 1865 818 808

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| <u>Title of each class</u>  | <u>Trade Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
|---|------------------------|--|
| American Depositary Shares<br>Ordinary shares, nominal value £0.000025 per share* | VACC                   | The Nasdaq Global Market                         |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

\*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

---

---

---

## EXPLANATORY NOTE

On May 13, 2022, Vaccitech plc (the “Company”) filed with the Securities and Exchange Commission (“SEC”) a Current Report on Form 8-K (“Original Form 8-K”) to disclose that it had dismissed BDO LLP (“BDO”) as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm. The Company provided BDO with a copy of the disclosures it made in the Original Form 8-K and requested that BDO furnish a letter addressed to the SEC stating whether it agrees with the statements made therein. This Form 8-K/A amends the Original Form 8-K solely to include a copy of BDO’s letter, dated May 20, 2022, which is filed as Exhibit 16.1 to this Form 8-K/A.

Except as described above, all other information in the Original 8-K remains unchanged.

### **Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

[16.1](#) [Letter from BDO LLP, dated May 20, 2022](#)  
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Vaccitech plc

Date: May 24, 2022

By: /s/ William Enright  
William Enright  
Chief Executive Officer

---



Tel: +44 (0)20 7486 5888  
Fax: +44 (0)20 7487 3686  
DX 9025 West End W1  
www.bdo.co.uk

55 Baker Street  
London W1U 7EU

May 20, 2022

Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549  
United States of America

We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on May 10, 2022, filed by our former client, Vaccitech plc. We agree with the statements made in response to that Item insofar as they relate to our Firm.

Very truly yours,

/s/ BDO LLP

BDO LLP

BDO LLP, a UK limited liability partnership registered in England and Wales under number OC305127, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms. A list of members' names is open to inspection at our registered office, 55 Baker Street, London W1U 7EU. BDO LLP is authorised and regulated by the Financial Conduct Authority to conduct investment business.

---